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Abstract
We report the case of an Epstein-Barr virus (EBV)- and human immunodeﬁciency virus-serum negative
patient suffering from repeatedly relapsing classical Hodgkin’s Lymphoma (cHL) associated with a histolog-
ical picture of plasma cell-hyaline vascular (PC-HV) form of Castleman’s disease (CD). The CD30- and
CD15- positive, Reed-Sternberg⁄Hodgkin cells, only occasionally expressed the CD20 molecule, but not
leukocyte common antigen and latent membrane protein-1. Single-strand polymerase chain reaction failed
to detect human herpesvirus 8 or EBV in the involved tissues. At the time of second relapse in July 2005,
the clinical picture was characterized by a palpable right hypogastric mass, disclosed at physical exam, in
the absence of other enlarged peripheral lymph nodes, subjective symptoms or laboratory proﬁle altera-
tions. Combined hybrid-(18)F-ﬂuorodeoxyglucose positron emission-computerized tomography (18F-FDG
PET⁄CT) showed increased radionuclide uptake in multiple external iliac lymph nodes [standardized uptake
value (SUV) of 7.4] and non-palpable left supraclavicular lymph nodes (SUV of 5.8). Relapsing cHL in the
context of mixed PC-HV CD was documented in two of three surgically excised abdominal lymph nodes
never previously enlarged or involved by any lymphoproliferative disease. Because of the limited disease
extension and failure to induce continuous remission with previous conventional chemoradiotherapy, the
patient was treated with six rituximab injections. This immunotherapy induced signiﬁcant reduction in size
of supraclavicular lymph nodes as evident at ultrasound (US) scan (<1 vs. 2.5 cm, post- vs. pretherapy),
which was conﬁrmed by the 18F-FDG PET⁄CT in October 2005, despite no modiﬁcation in SUV of 4.2.
18F-FDG PET⁄CT also disclosed no radionuclide uptake by abdominal lymph nodes. Thus, a second course
of four additional rituximab injections was given and subsequent 18F-FDG PET⁄CT indicated persistent,
but reduced incorporation of radionuclide compared to the pretherapy value (SUV of 2.7) in the supra-
clavicular area and conﬁrmed a normal metabolic activity in the iliac external lymph nodes. Because of
uncertain persistent disease in the supraclavicular nodal site, involved-ﬁeld radiotherapy (RT) was delivered
in that area as consolidation treatment. After completion of rituximab and RT for 16 and 14 months respec-
tively, US and 18F-FDG PET⁄CT exams were indicative of complete remission. This case is in concordance
with previously published data suggesting that rituximab immunotherapy might be a valid option in the
treatment of CD and also have a role in the management of relapsing cHL.
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In October 2001, a 27 yr-old woman, in documented
complete remission (CR) of classical Hodgkin lymphoma
(cHL) diagnosed 16 months before, presented at routine
follow-up computerized tomography (CT) scan with ﬁve
enlarged abdominal lymph nodes also detected when the
initial diagnosis of lymphoma was made. The patient was
asymptomatic and routine laboratory tests were normal.
In July 2000, at the beginning of clinical history, the
patient complained, in an otherwise well being status, a
rubbery, swelling, non-tender left supraclavicular enlar-
ged lymph node. Increased levels of erythrocyte sedimen-
tation rate (ESR) (103 mm⁄h), blood copper [400 lg⁄dL;
upper normal limit (UNL): 152], C-reactive protein
(CRP) (4.82 mg⁄dL; UNL: 0.5), IgG (2100 mg⁄
dL; UNL: 1600), polyclonal c-globulins (2.01 g⁄L; UNL:
1.52 g⁄L) and a2-globulins (1.34 g⁄L; UNL: 1.08 g⁄L),
as well as microcytic-hypochromic anemia (Hb 10.1 g⁄
dL) due to iron deﬁciency, were also recorded at that
time. CT scan revealed enlarged lymph nodes in the
upper- (bilateral laterocervical and supraclavicular,
mammary and mediastinal) and in the sub-diaphragmatic
(interaorto-caval and hepatic hilar) regions. Histology of
left supraclavicular lymph node showed intense follicular
hyperplasia, preserved germinal centers and expansion of
the interfollicular area containing small lymphocytes,
plasma cells, eosinophiles and classical Reed-Sternberg
and Hodgkin (RS⁄H) and ‘lacunar’ variant cells, expres-
sing CD15, CD30, only occasionally CD20, but not
leukocyte common antigen (LCA) and latent membrane
protein-1.
Lymphoma involvement of the bone marrow was
excluded histologically on posterior iliac crest biopsy spec-
imen. Based on these clinico-pathological ﬁndings, a diag-
nosis of nodular sclerosis, stage III A, non-bulky cHL
was made. The international prognostic index score was
2. Of note, the patient was Epstein-Barr virus (EBV)- and
human immunodeﬁciency virus (HIV)-serum negative.
Thus, six courses of adriamycin, bleomicin, vinblastin
and dacarbazine (ABVD) chemotherapy were adminis-
tered from August 2000 to January 2001. Rapid normali-
zation of laboratory abnormalities was observed during
treatment and post-therapy CT scan documented com-
plete regression of all pathological lymph nodes. How-
ever, persistent post-chemotherapy active disease in the
mediastinum was suggested by
67Gallium (Ga) uptake.
After radiotherapy (RT) (3000 cGy) delivered from Feb-
ruary to March 2001 to the involved mediastinal region
and extended to the supraclavicular area bilaterally, no
residual lymphoma could be detected by the subsequent
67Ga-Single Photon Emission Computed Tomography
(SPECT) exam, while second post-therapy CT scan
conﬁrmed complete regression of all adenopathy.
According to patient’s history, relapsing lymphoma
was the favored hypothesis in the interpretation of the
CT ﬁndings noted in October 2001. However, several
considerations raised the question of whether those
enlarged lymph nodes could reﬂect ab initio other condi-
tions, such as reactive lymphoma-associated adenopathy
or atypical lymphoproliferative disease concomitant with
HL. In fact, multiple laboratory abnormalities, some of
which not completely typical for HL, such CRP values
more than nine times above the UNL, increased IgG,
a2 and polyclonal c-globulin values, were noted at the
time of diagnosis. Moreover, initial disease was more
extensive in the upper- than in the sub-diaphragmatic
region in terms of number and size of the involved
lymph nodes.
Thus, a ‘non-operative’ strategy was adopted in the
hypothesis that subsequent evolution could eventually
clarify the nature of the enlarged nodes, and careful
watch-and-wait policy was therefore undertaken. The
patient remained asymptomatic,
67Ga-SPECT repeated
in January 2002 showed no mediastinal disease, but CT
scan performed in April 2002 conﬁrmed the presence of
multiple enlarged lymph nodes, unmodiﬁed in number
and size, in comparison with those revealed 6 months
before. Laboratory tests showed slightly increased ESR
values (36 mm⁄h), but not other abnormalities. However,
in June 2002 combined hybrid-(18)F-ﬂuorodeoxyglucose
positron emission-computerized tomography (18F-FDG
PET⁄CT) disclosed increased radionuclide uptake with a
standardized uptake value (SUV) of 2.9 to 3.7 in the
same abdominal lymph nodes previously shown at CT-
scan.
Concordance between 18F-FDG PET⁄CT and CT
scan ﬁndings strongly suggested the presence of active
disease in the abdominal lymph nodes and prompted the
execution of a laparoscopic nodal biopsy. However, the
histolgical picture was consistent with mixed hyperplastic
lymphadenitis (lymphoid follicles with germinal centers
formed by CD20-positive, but bcl2-negative cells, and
mild hyperplasia of the interfollicular area rich in CD3
expressing cells) and excluded relapsing HL.
Clinical-laboratory-radiological follow-up was there-
fore continued. From August 2002 to September 2003,
the patient referred a well being status and monthly-
performed physical examinations were normal. However,
a very slowly progressive increase in size of the abdomi-
nal enlarged lymph nodes was revealed by the CT exams
in October 2002, December 2002 and April 2003 while
hepatosplenomegaly, mediastinal, laterocervical or other
superﬁcial adenopathies were constantly absent. ESR
progressively increased up to 116 mm⁄h in September
2003 and serum copper values raised over normal
(204 mcg⁄dL). Slowly increasing CRP values
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hypochromic anemia (Hb = 10 g⁄dL) were also docu-
mented. In late September 2003 the patient complained
episodic mild arthralgias and paresthesias. Anti-nuclear
antibodies were positive with a granular pattern on
human epidermoid larynx carcinoma (HEP)-2 cell
(1 : 80), and for the ﬁrst time, hypoalbuminemia
(3.5 g⁄dL) was documented. Increased values of poly-
clonal c-globulins (2.93 g⁄L) and a2-globulins (1.29 g⁄L)
were also present, while extractable nuclear antigens,
Waaler-Rose assay and rheuma test were negative and
complement (C3, C4) serum levels, as well as phospho-
creatin kinase values, were normal. Similarly, electro-
myography did not show abnormalities. The CT scan
performed in October 2003 conﬁrmed the ﬁndings
revealed at previous exams and disclosed newly occurring
abdominal enlarged lymph nodes.
The observation of progressive worsening of labora-
tory parameters, increased size and number of lymph
nodes and the transient symptoms, not typical for HL,
prompted the excision of a further paracaval lymph node
in order to clarify the nature of the disease or condition
possibly responsible for those events.
Microscopic examination (Fig. 1A and B) showed
numerous lymphoid follicles, some of which with atro-
phic germinal centers crossed by several vessels (factor
VIII-positive and CD31-positive endothelial cells) with
hyaline walls and surrounded by concentric layers of
lymphocytes (LCA-positive). The germinal centers con-
sisted of CD20-positive cells (Fig. 2) and CD21-⁄CD35-
positive dendritic elements. Sheets of mature polyclonal
plasma cells and rare CD15-positive (Fig. 3), CD30-
positive, but CD20 )⁄+R S ⁄H cells (Fig. 4) in the
interfollicular area were detected. Those ﬁndings were
consistent with mixed plasma cell-hyaline vascular (PC-
HV) type Castleman’s disease (CD) or PC-HV-like CD
pathological changes and recurrent cHL. Bone marrow
examination revealed no RS⁄H cells, plasmocytosis or
other abnormalities. Diagnosis of relapsing stage IIA HL
was made. In order to better deﬁne the pathogenetic
biological background of those histological ﬁndings,
molecular studies were performed on genomic DNA,
extracted from formalin-ﬁxed tissues and tested for poly-
merase chain reaction (PCR) suitability by ampliﬁcation
of a 450 bp BCL-6 gene fragment. B-cell clonality was
determined by PCR analysis of both immunoglobulin
(Ig) heavy and light chain variable gene (IGV) rearrange-
ments (1). The PCR protocol, standardized to detect at
least ten clonal cells in a background of 10
4 cells, showed
the presence of a polyclonal pattern of rearrangements.
This was consistent with the policlonality of Ig light
chain found at immunohistochemical examination.
Human herpesvirus (HHV)-8 infection was evaluated
using single-strand PCR with primers KS330233-F and
(A)
(B)
Figure 1 (A) Small abnormal germinal center with concentric arrange-
ment of small lymphocytes and hypervascular interfollicular tissue rich
in plasma cells (HES, 10x). (B) Lacunar variant Reed⁄Sternberg and
Hodgkin cell at the periphery of the follicle (HES, 40x).
Figure 2 Lymphoid follicles with germinal centers in the context of
Castleman’s disease. Immunostaining for CD20 (10x).
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copies in a background of 15 000 cells (2), but viral
DNA was not detected in the tissue specimens analyzed.
The same PCR analysis performed for the EBV protein
EBNA-1 resulted negative.
Thus, ABVD chemotherapy was chosen, because of
patient’s previous good response to this regimen and
because we considered patient’s prognosis as related to
the relapsing lymphoma rather than to the CD patholog-
ical picture, being the latter either an autonomous lym-
phoproliferative disease or merely a HL-induced tissue
reactive modiﬁcation.
Because HL relapse was histologically proven
33 months after the completion of ﬁrst-line chemo-
therapy, in previously unirradiated lymph nodes, and
because of the absence of B symptoms, the indolent clini-
cal course, and the possibly increased incidence of infec-
tions in the course of autonomous, multicentric (M)-CD,
an autologous bone marrow transplantation was consid-
ered, but not judged as the ideal salvage therapy in this
case.
During chemotherapy, from December 2003 to May
2004, ESR and Hb values returned to normality
(10 mm⁄h and 14.1 g⁄dL) and a reduction in size and
number, but not disappearance, of the abdominal lymph
nodes was observed at CT scan after the second and
fourth cycle of therapy. As a total dose of adriamycine
of 500 mg⁄m
2 had already been administered, this drug
was substituted by liposomal doxorubicine for the last
two cycles. Because four residual enlarged lymph nodes
of (1–2 cm of diameter) were still documented at CT
scan after the completion of the sixth cycle of chemo-
therapy, another nodal excision was performed in order
to discriminate between lymphoma, and autonomous
CD involvement of those lymph nodes. The decision
was supported by the previous particularly indolent
patient clinical history and the need of planning further
therapy. Persistence of RS⁄H cells in the background of
mixed PC-HV type CD picture or CD-like histological
changes was documented. Thus, peripheral blood stem
cell (PBSC) mobilization and subsequent RT to involved
abdominal nodes were planned. PBSCs were successfully
mobilized in July 2004 (a total number of 201 · 10
4
CD34+ and 19.4 · 10
6 of CFU-GM cells, respectively)
using 16 lg⁄kg granulocyte-colony stimulating factor
daily for 8 d, including the 3 d of stem cell harvesting.
A second CR was achieved after RT (4000 cGy) deliv-
ered from August to September to the involved lymph
nodes, as displayed by 18F-FDG PET⁄CT in September
2004.
In July 2005, despite normality of laboratory tests,
physical examination revealed an isolated abdominal pal-
pable mass at the right side of the hypogastric region.
18F-FDG PET⁄CT scan revealed increased radionuclide
uptake in the right external iliac and non-palpable right
supraclavicular lymph nodes, but no other abnormalities,
with SUVs of 7.4 and 4.7 respectively. A new biopsy
revealed relapsing cHL in the context of mixed type CD
or CD-like changes in two of the three surgically excised
hypogastric adenopathies, the third showing a picture of
reactive lymphadenopathy.
The short duration of the second remission obtained
with conventional chemo- and RT suggested us to adopt
an alternative therapeutic approach. Once again, high
dose therapy with PBSC rescue was not judged as the best
salvage therapy, because of the limited extension of the
lymphoma at the time of this second relapse and the
increasing suspect of the existence of an autonomous form
of M-CD. In fact, it has been hypothesized that M-CD
may arise in a context of an immunoregulatory defect and
very little is known regarding the immunosuppressive
effects of high dose chemotherapy in this disease.
Figure 3 CD15-positive Reed⁄Sternberg and Hodgkin cells.
Figure 4 Reed⁄Sternberg and Hodgkin cells immunostained for
CD20.
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patients with CD, rituximab has been used with variable
success in the treatment of HHV-8-related or –unrelated
CD forms, in either HIV-positive or –negative patients.
It also was shown to produce clinical improvement and
an overall response rate of 22% in patients with relapsed
cHL in a pilot study from Younes et al. (3).
Based on such considerations, in August 2005 ritux-
imab therapy was started at a dose of 375 mg⁄m
2
weekly. Supraclavicular region was utilized to monitor
treatment efﬁcacy, being the easiest to evaluate with
ultrasound (US) scan and surgical scar hampered US
study of the abdominal nodes. US scan, performed after
two anti-CD20 injections, showed considerable reduction
in size of the supraclavicular lymph node (diameter
<1 cm), as compared to the pre-therapy evaluation
(diameter 2.5 cm). This lymph node shrinkage was also
documented after the fourth and sixth rituximab injec-
tion. PET⁄CT scan conﬁrmed reduced size of supracla-
vicular adenopathy, but no variation in 18F-FDG
incorporation (SUV of 4.2), while showing absence of
radionuclide uptake in the abdominal lymph nodes.
Because of patient well being, normality of all laboratory
tests and at least partial remission of the disease in
response to rituximab, four additional anti-CD20 injec-
tions were given 1 month later, determining an uncertain
CR, as indicated by reduced area of 18F-FDG incorpo-
ration, as well as decreased metabolic activity in the
supraclavicular area with a SUV of 2.7 and conﬁrmation
of the absence of radionuclide uptake in the abdominal
lymph nodes, respectively. Involved-ﬁeld RT (21 Gy, 14
fractions of 150 cGy) was administered to the former
area, as consolidation treatment in January 2006.
Repeated US and 18F-FDG PET⁄CT exams were indica-
tive of continuous CR after 16 and 14 months after the
completion of rituximab and RT, respectively.
Discussion
CD is a rare, heterogeneous clinico-pathological lympho-
proliferative disorder of unknown origin (4, 5). Histolog-
ical diversity is due to the existence of different variants
of the disease including the most common, pathologi-
cally-well deﬁned, hyaline vascular (HV) form, the less
frequent plasma cell (PC) type, the composite HV-PC
type and the plasmablastic (PB) type (4, 5). The anato-
mo-clinical pattern of CD can vary from a localized mass
to a systemic disorder with widespread adenopathy with
or without splenomegaly (4, 5).
These histological subtypes correlate with recognized
clinical syndromes. The HV type is usually characterized
by a single large solitary mass, indolent clinical behavior
and absence of constitutional symptoms, while the PC
variant, in either localized or multicentric clinical presen-
tation, is often associated with constitutional symptoms,
autoimmune manifestations, recurring infections and lab-
oratory abnormalities. The PC-multicentric type can be
characterized by a multi-relapsing, chronic non-progres-
sive or rapidly fatal course. Finally, the PB form is char-
acterized by the presence of plasmablasts that express
HHV-8 latent nuclear antigen and is found mostly in
HIV-positive patients. It consists in all cases, of a sys-
temic and symptomatic, clinically aggressive disease (4,
5). This overall diversity might reﬂect different etiopatho-
genetic mechanisms (5, 6).
CD can occur as an autonomous pathologic entity
(primary CD). However, CD-like histological picture can
be found in association with other nosologically well
deﬁned diseases (4, 5). Thus, the term of secondary M-
CD utilized by some, but not all, pathologists identiﬁes
all the cases in which the clinico-pathologic complex of
this disorder is associated with other pathological condi-
tions. In these cases there is a prevalence of the PC form
in the ﬂorid proliferative phase or in the spent HV-like
evolutive state of the involved lymph nodes (4).
The non-speciﬁc nature of the pathologic features of
PC-CD along with clinico-laboratory manifestations that
this variant shares with many other inﬂammatory and
lymphoproliferative disorders makes the occurrence of
PC-CD-like changes a frequently described event in the
literature (4). HL is described with adjacent CD-like
changes or in association with CD or CD-like changes
(5, 7–10).
The fact that such an association was observed at ﬁrst
relapse in the case described, might reﬂect the true coex-
istence of two autonomous diseases. Overtime repeated
observations of only rare RS⁄H cells in the predominant
context of a PC-HV histology and the absence of CD
changes at the time of diagnosis support this hypothesis.
However, it is not possible to exclude the coexistence of
cHL and CD histological picture ab initio in adjacent
lymph nodes not sampled. Alternatively, the histological
CD changes might be the result of the hyperactivation of
benign B-lymphocytes that form cellular background of
HL involved tissue along with PCs and T-lymphocytes.
In fact, many pathologists believe that the so called sec-
ondary forms of CD are merely the ﬁnal end point of
the interleukine (IL)-6-induced environment and not an
autonomous disorder.
Overproduction of IL-6, vascular-endothelial growth
factor (VEGF) and other cytokines (4, 5, 11, 12) is
thought to be responsible for the clinicopathologic com-
plex common to all these conditions. This pathogenetic
hypothesis represents the rationale for immunotherapy
approaches targeting IL-6 or its receptor. Both murine
anti-human IL-6 monoclonal antibody and humanized
IL-6 receptor antibody alleviated symptoms, normalized
biochemical parameters and reduced lymphoadenopathies
Falchi et al. Response to rituximab of associated Hodgkin’s lymphoma and Castleman’s disease
ª 2007 The Authors
Journal compilation 79 (455–461) ª 2007 Blackwell Munksgaard 459associated with M-CD (13, 14). These effects were dura-
ble when therapy was extended over a prolonged time
period (14). Another immunotherapy approach consists
in the use of rituximab (15–22). This treatment produces
variably successful control of HHV8-related or unrelated,
primary or secondary M-CD forms, irrespective of host’s
HIV infection status. Furthermore, the activity of ritux-
imab in patients with HHV8-unrelated form was docu-
mented in cases with either elevated or normal levels of
this molecule. The therapeutic mechanism of rituximab
consists in targeting and depleting CD20-positive B cells
which are directly or indirectly responsible for the deregu-
lated production of human IL-6, VEGF and other cyto-
kines (4, 5, 11, 12). This mechanism of rituximab is also
advocated to explain its effect in patients with relapsed
cHL (3). In fact, some observations indicate that benign
B-lymphocytes, in addition to activated T-cells inﬁltrating
cHL lesions may contribute to the survival of RS⁄H cells
in vivo (23, 24).
In favor of this view stands the observation that no
HHV8 infection was detected in the cells obtained from
the lymph nodes simultaneously involved by histological
CD changes and cHL. On the other hand, RS⁄H cells
produce IL-6 (25), which is induced by EBV infection or
by non-viral activation of nuclear transcription factor
k-B (26). This second pathway is probably operating in
the EBV–negative case described above, whose indolent
clinical-laboratory features also suggest an IL-6 produc-
tion mainly limited to the lymph nodal environment,
being not a systemic event.
Irrespective of the ﬁnal interpretation of these patho-
logic ﬁndings, there was evidence of rituximab efﬁcacy in
our patient. This monoclonal antibody probably targeted
and depleted the CD20-positive lymphocytes inﬁltrating
the lymphoma involved tissue and perhaps shared by HL
background and CD. Thus, purging of CD20-positive
cells with rituximab might have deprived RS⁄H cells of a
survival factor. This conclusion is reinforced by the
immunophenotype of RS⁄H cells that did not or only
rarely expressed the CD20 molecule and therefore were
not the primary target of rituximab.
The overall very indolent clinical evolution, along
with the lack of spleen and liver involvement and the
pattern of relapsing diseases (cHL and CD) remaining
conﬁned to few nodal sites even at the time of second
relapse, when anatomical areas in both sides of dia-
phragm were involved, may have favored the response
to rituximab.
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